NEUVIS
DEAD

Serial Number

79268366

Owner

AusCann Group Holdings Ltd

Attorney

Charles G. Zug

Filing Date

Jul 31, 2019

Add to watchlist:

No watchlists yet
View on USPTO

NEUVIS Trademark

Serial Number: 79268366

NEUVIS is a trademark filed by AusCann Group Holdings Ltd on July 31, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

AusCann Group Holdings Ltd

Level 2, Suite 8 Shenton House,

Entity Type: 99

Trademark Details

Filing Date

July 31, 2019

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for prevention, management or treatment of inflammatory disorders, neurological disorders, psychiatric disorders, malignancy, immune disorders, metabolic disorders, infectious diseases, gastrointestinal disorders, cardiovascular disorders, cancer, pain; Pharmaceutical preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavior modification, schizophrenia, bi-polar disorder, pain; Veterinary preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Plant extracts for medical, pharmaceutical and veterinary use; Biochemical and biological products, in the nature of terpenophenolics, terpenoids and flavones for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Biochemical and biological products, namely, terpenophenolics, terpenoids and flavones for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical preparations for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical preparations for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Analgesic preparations; Anti-inflammatory preparations; Anti-microbial preparations for inhibiting microbiological growth and infection in medical and veterinary situations; Anti-nauseants treatment preparations; Anti-spasmodics; Anticonvulsants; Appetite stimulant preparations for medical purposes; Nausea medications, namely, nausea treatment preparations

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 27, 2023 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Aug 4, 2023 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 4, 2023 FICR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 4, 2022 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Aug 4, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 4, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 21, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 21, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 21, 2022 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 15, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 14, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 14, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 14, 2021 GNRN
NON-FINAL ACTION E-MAILED
Apr 14, 2021 GNRT
NON-FINAL ACTION WRITTEN
Apr 14, 2021 CNRT
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 20, 2021 OPNX
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 9, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 9, 2021 TROA
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 3, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 3, 2021 OPNR
REFUSAL PROCESSED BY IB
Sep 26, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 9, 2020 RFCS
REFUSAL PROCESSED BY MPU
Aug 28, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 25, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 24, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 17, 2020 DOCK
ASSIGNED TO EXAMINER
Nov 5, 2019 DOCK
ASSIGNED TO EXAMINER
Oct 25, 2019 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 8, 2019 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 4, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 26, 2019 REPR